Should I buy Moderna for my Stocks and Shares ISA?

Rupert Hargreaves explains why he thinks the Moderna share price could be an attractive acquisition for his Stocks and Shares ISA today.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

I like to invest in growth equities using my Stocks and Shares ISA. The tax benefits provided by this wrapper mean I do not have to worry about any capital gains tax on these assets if they appreciate substantially. And with that in mind, I have recently been taking a closer look at the Moderna (NASDAQ: MRNA) share price. 

Stocks and Shares ISA investment

Before 2020, few investors had heard about this enterprise. Outside of the biotechnology industry, the company was relatively unknown. However, it shot to fame after its coronavirus vaccine became one of the first to receive approval last year. 

Syringe and vial on blue background

Since then, the company has become a household name. The Moderna share price has reflected this growth. The stock has risen a staggering 1,800% since the beginning of 2020. 

As the company’s vaccine has been rolled out around the world, sales and profits have jumped. For the fourth quarter of 2020, Moderna reported sales of $570m and a net loss of $270m. In the second quarter of 2021, revenues totalled $4.3bn, and net income surged to $3bn. 

Based on these numbers, analysts believe the stock is trading at a forward price-to-earnings (P/E) multiple of 15. I do not think that looks too expensive for a cutting-edge biotechnology company. 

That being said, the demand for Covid vaccines may fall in the long run. As other companies bring their treatments to market, competition could increase. This would push down prices and overall demand for Moderna’s product. 

The outlook for the Moderna share price

Competition is a risk to the company’s growth, but when looking for investments for my Stocks and Shares ISA, I focus on each asset’s long-term potential. 

In the case of Moderna, I think the coronavirus vaccine is just the start. As of March 2021, the company had 13 programmes in clinical trials and a total of 24 development programmes researching vaccines based on its proprietary RNA technology.

Moreover, the Covid vaccine helped prove the RNA technology. It is now providing a steady stream of cash for the company to invest back into treatment development. 

Considering all of the above, I would buy the company as a speculative investment for my Stocks and Shares ISA. Now the group has proven its technology, there is no telling how many other products it could create using the same method.

As well as this growth potential, the Moderna share price also appears cheap based on its current profitability. That is without giving any consideration to future growth.

I would only buy the asset as a speculative stock because I know just how unpredictable the drug development and commercialisation process can be.

Moderna might have some promising treatments under development, but there is no guarantee they will ever make it to market. The success of the coronavirus vaccine has helped de-risk RNA technology, but it has not eliminated the risk. I will be keeping this in mind going forward. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves has no position in any of the shares mentioned. The Motley Fool UK has recommended Moderna Inc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

5 steps to start buying shares with under £500

Learn how this writer would start buying shares with a few hundred pounds in a handful of steps, if he…

Read more »

Young happy white woman loading groceries into the back of her car
Investing Articles

The FTSE 100 offers some great bargains. Is this one?

Our writer digs into one FTSE 100 share that has had a rough 2024 to date, ahead of its interim…

Read more »

Smiling white woman holding iPhone with Airpods in ear
Investing Articles

£9,000 of savings? Here’s my 3-step approach to aim for £1,794 in passive income

Christopher Ruane walks through the practical steps he would take to try and turn £9,000 into a sizeable passive income…

Read more »

Group of young friends toasting each other with beers in a pub
Investing Articles

I’d buy 29,412 shares of this UK dividend stock for £150 a month in passive income

Insiders have been buying this dividend stock, which offers an 8.5% yield. Roland Head explains why he’d choose the shares…

Read more »

Red briefcase with the words Budget HM Treasury embossed in gold
Investing Articles

Could the new UK budget spell growth for these 6 FTSE stocks? I think so!

Mark David Hartley considers six UK stocks that could enjoy growth off the back of new measures announced in the…

Read more »

Investing Articles

With a 6.6% yield, is now the right time to add this income stock to my ISA?

Our writer’s looking to boost his Stocks and Shares ISA. With this in mind, he’s debating whether to buy a…

Read more »

Dividend Shares

This blue-chip FTSE stock just fell 12.5% in a day. Is it time to consider buying?

Smith & Nephew is a well-known, blue-chip FTSE stock with a decent dividend yield. And its share price just dropped…

Read more »

Investing Articles

At 72p, the Vodafone share price looks to be at least 33% undervalued to me

Our writer looks at a number of valuation measures to determine whether the Vodafone share price reflects the fair value…

Read more »